Literature DB >> 27596950

TSPO activation modulates the effects of high pressure in a rat ex vivo glaucoma model.

Makoto Ishikawa1, Takeshi Yoshitomi2, Douglas F Covey3, Charles F Zorumski4, Yukitoshi Izumi4.   

Abstract

We previously reported that elevated pressure induces axonal swelling and facilitates the synthesis of the neurosteroid, allopregnanolone (AlloP), in the ex vivo rat retina. Exogenously applied AlloP attenuates the axonal swelling, suggesting that the neurosteroid plays a neuroprotective role against glaucomatous pressure-induced injuries, although mechanisms underlying neurosteroidogenesis have not been clarified. The aim of this study was to determine whether AlloP synthesis involves activation of translocator protein 18 kD (TSPO) and whether TSPO modulates pressure-induced retinal injury. Ex vivo rat retinas were exposed to various pressures (10, 35, or 75 mmHg) for 24 h. Expression of TSPO, 5α-reductase (5aRD), and AlloP was examined by quantitative real-time RT-PCR, ELISA, immunohistochemistry, and LC-MS/MS. We also examined the effects of TSPO ligands on AlloP synthesis and retinal damage. In this acute model, quantitative real-time RT-PCR and ELISA analyses revealed that elevated pressure facilitated TSPO expression. Similarly, these methods also detected enhanced 5aRD (mostly type II), which was observed in retinal ganglion cells (RGC) and the inner nuclear layer (INL). Atriol, a TSPO antagonist, suppressed pressure mediated AlloP synthesis and induced more severe histological changes in the inner retina when combined with elevated pressure. PK11195, a TSPO ligand that facilitates AlloP synthesis by itself, remarkably diminished pressure-mediated retinal degeneration. These results suggest that AlloP synthesis is induced by sequential activation of TSPO and 5aRD in an ex vivo glaucoma model, and that TSPO agonists may serve as potential therapeutic agents for the prevention of pressure-induced retinal damage.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  5α-reductase; Allopregnanolone; Glaucoma; Neuroprotection; Neurosteroid; TSPO

Mesh:

Substances:

Year:  2016        PMID: 27596950      PMCID: PMC5473616          DOI: 10.1016/j.neuropharm.2016.09.001

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  63 in total

Review 1.  Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence.

Authors:  C E Marx; D W Bradford; R M Hamer; J C Naylor; T B Allen; J A Lieberman; J L Strauss; J D Kilts
Journal:  Neuroscience       Date:  2011-07-01       Impact factor: 3.590

2.  Primary angle-closure glaucoma. A review 5 years after bilateral surgery.

Authors:  R F Lowe
Journal:  Br J Ophthalmol       Date:  1973-07       Impact factor: 4.638

3.  Concurrent downregulation of a glutamate transporter and receptor in glaucoma.

Authors:  R Naskar; C K Vorwerk; E B Dreyer
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-06       Impact factor: 4.799

4.  N-methyl-D-aspartate receptors of ganglion cells in rabbit retina.

Authors:  S C Massey; R F Miller
Journal:  J Neurophysiol       Date:  1990-01       Impact factor: 2.714

Review 5.  Peripheral benzodiazepine receptors and mitochondrial function.

Authors:  Pierre Casellas; Sylvaine Galiegue; Anthony S Basile
Journal:  Neurochem Int       Date:  2002-05       Impact factor: 3.921

6.  Downregulation of glutamine synthetase via GLAST suppression induces retinal axonal swelling in a rat ex vivo hydrostatic pressure model.

Authors:  Makoto Ishikawa; Takeshi Yoshitomi; Charles F Zorumski; Yukitoshi Izumi
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-22       Impact factor: 4.799

7.  Role of neurosteroids in regulating cell death and proliferation in the late gestation fetal brain.

Authors:  T Yawno; J J Hirst; M Castillo-Melendez; D W Walker
Journal:  Neuroscience       Date:  2009-07-08       Impact factor: 3.590

8.  Retinal glutamate transporter changes in experimental glaucoma and after optic nerve transection in the rat.

Authors:  Keith R G Martin; Hana Levkovitch-Verbin; Danielle Valenta; Lisa Baumrind; Mary Ellen Pease; Harry A Quigley
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-07       Impact factor: 4.799

9.  Retinal ganglion cell neuroprotection induced by activation of alpha7 nicotinic acetylcholine receptors.

Authors:  David Mata; David M Linn; Cindy L Linn
Journal:  Neuropharmacology       Date:  2015-07-31       Impact factor: 5.250

Review 10.  Neurosteroids, stress and depression: potential therapeutic opportunities.

Authors:  Charles F Zorumski; Steven M Paul; Yukitoshi Izumi; Douglas F Covey; Steven Mennerick
Journal:  Neurosci Biobehav Rev       Date:  2012-10-17       Impact factor: 8.989

View more
  5 in total

1.  The neurosteroid allopregnanolone protects retinal neurons by effects on autophagy and GABRs/GABAA receptors in rat glaucoma models.

Authors:  Makoto Ishikawa; Sanae Takaseki; Takeshi Yoshitomi; Douglas F Covey; Charles F Zorumski; Yukitoshi Izumi
Journal:  Autophagy       Date:  2020-02-27       Impact factor: 16.016

2.  Additive neuroprotective effects of 24(S)-hydroxycholesterol and allopregnanolone in an ex vivo rat glaucoma model.

Authors:  Makoto Ishikawa; Takeshi Yoshitomi; Douglas F Covey; Charles F Zorumski; Yukitoshi Izumi
Journal:  Sci Rep       Date:  2018-08-27       Impact factor: 4.379

3.  The Enantiomer of Allopregnanolone Prevents Pressure-Mediated Retinal Degeneration Via Autophagy.

Authors:  Makoto Ishikawa; Toru Nakazawa; Hiroshi Kunikata; Kota Sato; Takeshi Yoshitomi; Kathiresan Krishnan; Douglas F Covey; Charles F Zorumski; Yukitoshi Izumi
Journal:  Front Pharmacol       Date:  2022-03-16       Impact factor: 5.810

Review 4.  Allopregnanolone: An overview on its synthesis and effects.

Authors:  Silvia Diviccaro; Lucia Cioffi; Eva Falvo; Silvia Giatti; Roberto Cosimo Melcangi
Journal:  J Neuroendocrinol       Date:  2021-06-29       Impact factor: 3.870

5.  A lab-on-a-chip model of glaucoma.

Authors:  Fatemeh Nafian; Babak Kamali Doust Azad; Shahin Yazdani; Mohammad Javad Rasaee; Narsis Daftarian
Journal:  Brain Behav       Date:  2020-08-16       Impact factor: 2.708

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.